Pre-ascent blood markers predicted acute mountain sickness after rapid ascent to 4,200 m
A prospective cohort of 297 healthy young Chinese men found that simple blood tests collected at 300 m altitude carried measurable predictive value for acute mountain sickness after a rapid ascent to 4,200 m. The study centered on pre-plateau albumin, uric acid, and the uric acid-to-albumin ratio, or UAR, and each showed moderate ability to discriminate who would develop symptoms on the plateau. In a setting where ascent is fast and physiologic adaptation is limited, even a modestly accurate predeparture marker could matter for field medicine, expedition planning, and altitude screening.
The cohort was young, healthy, and entirely male, with an average age of 20.88 ± 1.76 years. Baseline assessments were obtained at 300 m using questionnaires, on-site testing, and hematologic and biochemical measurements, then repeated assessment was performed on the second day after arrival at 4,200 m. AMS was defined stringently as a Lake Louise Score 2018 of at least 3 points plus headache. By that definition, 29.97% of participants met criteria for acute mountain sickness after arrival.
One sentence captures the clinical tension in this cohort: nearly one in three young men became symptomatic after rapid ascent.
Albumin, uric acid, and the altitude transition
The biologic appeal of these markers is straightforward. Albumin reflects nutritional status, inflammatory burden, and intravascular oncotic reserve, while uric acid sits at the intersection of oxidative stress, endothelial signaling, purine metabolism, and renal handling. At altitude, hypobaric hypoxia strains the autonomic system, pulmonary circulation, and cerebral perfusion, so pre-existing differences in vascular resilience may influence who tolerates the transition and who develops headache, dizziness, or related symptoms. A composite measure such as UAR may be especially informative because it captures two biochemical processes moving in opposite directions rather than relying on either marker alone.
Univariate logistic regression linked several baseline variables at 300 m with later AMS, including heart rate, alcohol consumption, albumin, and uric acid. After multivariable adjustment, pre-plateau albumin, uric acid, and UAR remained independently associated with risk. Their receiver operating characteristic curves were closely clustered, with area under the curve values of 0.710 for albumin, 0.701 for uric acid, and 0.711 for UAR, each with P < 0.001. Those values do not suggest perfect screening tools, but they do place the markers in a range that is clinically usable when the alternative is no biomarker at all.
The cut points identified by the Youden index were 47.25 g/L for albumin, 420.10 μmol/L for uric acid, and 7.45 for UAR. In practical terms, these thresholds offer a quick triage framework for clinicians or expedition teams who need to judge risk before ascent. They are not substitutes for acclimatization, but they could help identify who may need more caution, slower ascent, or closer monitoring once the group reaches high altitude.
UAR separated higher-risk subgroups more cleanly
UAR showed especially useful predictive performance in men with body mass index below 25 kg/m2, those with a history of low-altitude residence, and those who drank alcohol. Those subgroup findings matter because altitude susceptibility is rarely uniform. Lower body mass can coincide with smaller physiologic reserve, long-term low-altitude residence may limit prior acclimatization exposure, and alcohol use can complicate hydration, sleep, and cerebrovascular responses during ascent. A ratio that blends albumin and uric acid may therefore be better suited to real-world screening than either lab value in isolation.
The data also point to a broader pathophysiologic theme: acute mountain sickness likely emerges when individual reserve is outmatched by the speed of environmental change. Hypoxia can trigger sympathetic activation, vascular permeability shifts, sleep disruption, and headache pathways, and baseline biochemical differences may influence how sharply those responses unfold. Albumin may track with plasma volume and inflammatory state, while uric acid may reflect both oxidative stress and endothelial responses to hypoxic stress. In that context, the predictive signal is biologically plausible rather than incidental.
What the cohort can and cannot tell clinicians
This was a prospective design, which strengthens the temporal link between baseline biomarkers and later altitude illness. It also used a clearly defined outcome and a clinically familiar symptom score, making the endpoint relevant to bedside and expedition use. Even so, the study remains narrowly drawn: all participants were young, healthy, and male, and the findings cannot be assumed to apply to women, older adults, patients with chronic disease, or travelers with a very different acclimatization history. The data also reflect one ascent pattern to one altitude, so performance could shift with slower climbs, different environments, or repeated exposure.
The predictive performance is moderate rather than decisive. That is still useful, because AMS prevention often depends on risk stratification rather than binary diagnosis. A marker that nudges pretest probability upward can help decide who deserves more conservative ascent planning, more intensive observation, or stronger counseling about sleep, alcohol, and exertion before entering hypoxic conditions. In a practical field setting, that may be enough to influence decisions before symptoms begin.
One sentence should be stated plainly: these biomarkers predicted risk; they did not explain every case.
Why this matters for altitude screening
For clinicians advising young men heading quickly to high elevations, the appeal of albumin and uric acid lies in accessibility. Both tests are widely available, inexpensive, and already part of routine biochemical panels in many settings. The study suggests that a pre-ascent snapshot of systemic physiology may be more informative than history alone, particularly when the goal is to identify those likely to cross the threshold into clinically significant altitude illness within 48 hours of arrival.
The findings also invite a more nuanced view of risk assessment. A single number rarely captures the full biologic burden of hypoxia, but combining biochemical markers can improve discrimination enough to be useful. UAR, in particular, may deserve attention because it packages two altitude-relevant signals into one ratio and performed consistently across the overall cohort and selected subgroups.
What remains unanswered is whether acting on these markers changes outcomes. No data here show that using albumin, uric acid, or UAR to alter ascent plans prevents AMS, and the study does not establish a treatment target. The most defensible reading is narrower: among healthy young men rapidly climbing to 4,200 m, pre-plateau albumin, uric acid, and their ratio identified a measurable vulnerability to acute mountain sickness, with UAR offering the clearest signal in several clinically recognizable subgroups.